From both the U.S. and Chinese perspectives, the ICER for the inavolisib triple regimen is higher than the WTP threshold compared to palbociclib plus fulvestrant, making it not a cost-effective first-line treatment for PIK3CA-mutated HR+/HER2- advanced breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.